SBL
TMO icon

Sargent Bickham Lagudis’s Thermo Fisher Scientific TMO Stock Holding History

Sargent Bickham Lagudis’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.81M Buy
6,912
+122
+2% +$64.6K 0.31% 70
2022
Q3 		$3.44M Buy
6,790
+17
+0.3% +$9.51K 0.31% 67
2022
Q2 		$3.68M Sell
6,773
-372
-5% -$205K 0.32% 69
2022
Q1 		$4.22M Buy
7,145
+427
+6% +$245K 0.33% 66
2021
Q4 		$4.48M Buy
6,718
+311
+5% +$194K 0.34% 64
2021
Q3 		$3.66M Buy
6,407
+73
+1% +$40.1K 0.3% 73
2021
Q2 		$3.19M Sell
6,334
-197
-3% -$93K 0.26% 81
2021
Q1 		$2.98M Buy
6,531
+479
+8% +$229K 0.26% 78
2020
Q4 		$2.82M Buy
6,052
+320
+6% +$150K 0.26% 79
2020
Q3 		$2.53M Sell
5,732
-95
-2% -$39.2K 0.25% 78
2020
Q2 		$2.11M Buy
5,827
+1,211
+26% +$406K 0.23% 87
2020
Q1 		$1.31M Buy
4,616
+4,132
+854% +$1.3M 0.17% 100
2019
Q4 		$157K Buy
484
+29
+6% +$8.79K 0.02% 231
2019
Q3 		$133K Sell
455
-60
-12% -$17.2K 0.02% 225
2019
Q2 		$151K Buy
515
+60
+13% +$16.5K 0.02% 230
2019
Q1 		$125K Hold
455
– – 0.01% 257
2018
Q4 		$102K Buy
455
+130
+40% +$30.5K 0.01% 269
2018
Q3 		$79K Hold
325
– – 0.01% 306
2018
Q2 		$67K Hold
325
– – 0.01% 317
2018
Q1 		$67K Sell
325
-53
-14% -$11.1K 0.01% 315
2017
Q4 		$72K Buy
378
+53
+16% +$10.2K 0.01% 314
2017
Q3 		$61K Hold
325
– – 0.01% 343
2017
Q2 		$57K Buy
325
+25
+8% +$4.2K 0.01% 342
2017
Q1 		$46K Hold
300
– – 0.01% 374
2016
Q4 		$42K Sell
300
-150
-33% -$22.1K 0.01% 367
2016
Q3 		$72 Buy
450
+10
+2% +$1.54K 0.01% 293
2016
Q2 		$65K Buy
440
+40
+10% +$5.9K 0.01% 310
2016
Q1 		$57K Buy
+400
New +$53.6K 0.01% 344

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sargent Bickham Lagudis's TMO Position: Q4 2022 in Review

Sargent Bickham Lagudis increased its Thermo Fisher Scientific (TMO) stake by 1.8% in Q4 2022, buying an estimated $64.6K and bringing the position to 6,912 shares worth $3.81M. The position accounts for 0.31% of the portfolio, ranked #70.

Sargent Bickham Lagudis first reported a position in TMO in Q1 2016 and has held it in 28 quarters since. The position peaked at $4.48M in Q4 2021. 2,374 funds tracked by Wall St. Rank hold TMO as of Q4 2022.

  • Sargent Bickham Lagudis held 6,912 shares of Thermo Fisher Scientific worth $3.81M as of Q4 2022.
  • Sargent Bickham Lagudis bought 122 Thermo Fisher Scientific shares in Q4 2022, an estimated $64.6K.
  • Thermo Fisher Scientific made up 0.31% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #70 holding.
  • Sargent Bickham Lagudis first reported a position in Thermo Fisher Scientific in Q1 2016 and has held it in 28 quarters since.
  • Sargent Bickham Lagudis's Thermo Fisher Scientific position peaked at $4.48M in Q4 2021.
  • 2,374 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.